Voyager Therapeutics(VYGR) - 2023 Q4 - Annual Results

– Company had approximately $431 million in pro-forma cash as of December 31, 2023, adjusted for $100 million consideration from Novartis agreements and $100 million public offering – – Strong cash position and anticipated milestones/reimbursements provide runway into 2027, potentially enabling the generation of clinical data from multiple programs – EXHIBIT 99.1 Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results Key Milestones Achieved in Q4 2023 and Subsequent P ...